经皮雌二醇不会损害绝经后女性的止血生物标志物。

Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women.

作者信息

Martínez Carlos, Basurto Lourdes, Zárate Arturo, Saucedo Renata, Gaminio Elizabeth, Collazo Juan

机构信息

Endocrine Research Unit, Centro Medico Nacional, Instituto Mexicano del Seguro Social, and Thrombosis and Hemostatic Unit, Hospital de México, Agrarismo 208-601, México DF 11800, Mexico.

出版信息

Maturitas. 2005 Jan 10;50(1):39-43. doi: 10.1016/j.maturitas.2004.03.011.

DOI:10.1016/j.maturitas.2004.03.011

PMID:15590212

Abstract

OBJECTIVE

To evaluate the effect of transdermal estradiol therapy (ET) on coagulation and fibrinolysis markers in postmenopausal women.

METHODS

Prospective open trial study in 59 healthy hysterectomized postmenopausal women. Thirty women received transdermal ET (50 microg per day) during 3 months and 29 women formed the untreated arm.

RESULTS

Baseline factor VII-tissue factor complex (VIIa-rTF), fibrinogen and plasminogen activator inhibitor-1 (PAI-1) levels decreased significantly (P < 0.01) after therapy. In contrast, tissue-type plasminogen activator antigen (t-PA) levels increased significantly (P < 0.01). After ET, there was no difference in protein C activity (PC), protein S activity (PS), plasminogen (PLG), and antithrombin III (ATIII) levels. None of participants reported thromboembolic events.

CONCLUSION

ET elicited a decrement in blood biomarkers implicated in coagulation activation which in turn seemed to improve fibrinolytic activity. These results suggest that transdermal route does not impair thrombotic risk.

摘要

目的

评估经皮雌二醇治疗（ET）对绝经后女性凝血和纤溶指标的影响。

方法

对59名健康的绝经后子宫切除女性进行前瞻性开放试验研究。30名女性在3个月内接受经皮ET治疗（每天50微克），29名女性作为未治疗组。

结果

治疗后，基线时的凝血因子VII - 组织因子复合物（VIIa - rTF）、纤维蛋白原和纤溶酶原激活物抑制剂-1（PAI - 1）水平显著降低（P < 0.01）。相比之下，组织型纤溶酶原激活物抗原（t - PA）水平显著升高（P < 0.01）。ET治疗后，蛋白C活性（PC）、蛋白S活性（PS）、纤溶酶原（PLG）和抗凝血酶III（ATIII）水平无差异。所有参与者均未报告血栓栓塞事件。